Document is current
Any future updates will be listed below
-
Authors
Havel, Václav http://orcid.org/0000-0002-6911-4669
Kruegel, Andrew C.
Bechand, Benjamin
McIntosh, Scot
Stallings, Leia
Hodges, Alana
Wulf, Madalee G.
Nelson, Mel
Hunkele, Amanda
Ansonoff, Michael
Pintar, John E. http://orcid.org/0000-0001-5945-569X
Hwu, Christopher
Ople, Rohini S.
Abi-Gerges, Najah http://orcid.org/0000-0001-9824-1694
Zaidi, Saheem A.
Katritch, Vsevolod http://orcid.org/0000-0003-3883-4505
Yang, Mu http://orcid.org/0000-0002-1530-829X
Javitch, Jonathan A. http://orcid.org/0000-0001-7395-2967
Majumdar, Susruta http://orcid.org/0000-0002-2931-3823
Hemby, Scott E. http://orcid.org/0000-0002-6987-1133
Sames, Dalibor http://orcid.org/0000-0001-6911-2260
- License Information
-
More Information
Article History
Received: 7 September 2023
Accepted: 16 August 2024
First Online: 20 September 2024
Competing interests
: V.H., A.C.K, B.B., M.G.W, J.A.J., S.E.H and D.S. are named inventors on a patent(s) related to oxa-iboga compounds. A.C.K and D.S. are co-founders of Gilgamesh Pharmaceuticals, which licensed the oxa-iboga assets from Columbia University. All other authors declare no competing interests.
